Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
AbstractAcute myeloid leukemia (AML) is a myeloid malignancy carrying a heterogeneous molecular panel of mutations participating in the blockade of differentiation and the increased proliferation of myeloid hematopoietic stem and progenitor cells. The historical “3 + 7” treatment (cytarabine and daunorubicin) is currently challenged by new therapeutic strategies, including drugs depending on the molecular landscape of AML. This panel of mutations makes it possible to combine some of these new treatments with conventional chemotherapy. For example, the FLT3 receptor is overexpressed or mutated in 80% or 30% of AML, respectively. Such anomalies have led to the development of targeted therapies using tyrosine kinase inhibitors (TKIs). In this review, we document the history of TKI targeting, FLT3 and several other tyrosine kinases involved in dysregulated signaling pathways. View Full-Text
Share & Cite This Article
Fernandez, S.; Desplat, V.; Villacreces, A.; Guitart, A.V.; Milpied, N.; Pigneux, A.; Vigon, I.; Pasquet, J.-M.; Dumas, P.-Y. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How? Int. J. Mol. Sci. 2019, 20, 3429.
Fernandez S, Desplat V, Villacreces A, Guitart AV, Milpied N, Pigneux A, Vigon I, Pasquet J-M, Dumas P-Y. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How? International Journal of Molecular Sciences. 2019; 20(14):3429.Chicago/Turabian Style
Fernandez, Solène; Desplat, Vanessa; Villacreces, Arnaud; Guitart, Amélie V.; Milpied, Noël; Pigneux, Arnaud; Vigon, Isabelle; Pasquet, Jean-Max; Dumas, Pierre-Yves. 2019. "Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?" Int. J. Mol. Sci. 20, no. 14: 3429.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.